N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: Novel insights and clinical perspectives

Psychopharmacology

Volumn 179, Issue 1, 2005, Pages 30-53

  Millan, Mark J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Antipsychotic; D Cycloserine; D Serine; GlycineB; Kynurenate; NMDA; Schizophrenia

Indexed keywords

7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; CYCLOSERINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; ORG 24598; RISPERIDONE; S 18841; SARCOSINE; SSR 504734; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; GLYCINE; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SERINE;

EID: 17744399498     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-2199-1     Document Type: Review

References (327)

1. Abel KM, Allin MPG, Hemsley DR, Geyer MA (2003) Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 44:729-737
2. Adell A, Artigas F (2004) The somatodentritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci Biobehav Res 28:415-431
3. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A (1999) Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156:1646-1649
4. Aghajanian GK, Marek GJ (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Interactive 31:302-312
5. Ahmadi S, Muth-Selbach U, Lauterbach A, Lipfert P, Neuhuber WL, Zeilhofer HU (2003) Facilitation of spinal NMDA receptor currents by spillover of synaptically released glycine. Science 300:2094-2097
6. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney WE, Jones EG (1996) Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenia. J Neurosci 16:19-30
7. 7 nicotinic receptors in the hippocampus. J Neurosci 24:4635-4648
8. Anand A, Charney D, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Arch Gen Psychiatry 57:270-276
9. Andersen JD, Pouzet B (2004) Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine. Neuropsychopharmacology 29:1080-1090
10. Andersen JM, Lindberg V, Myhrer T (2002) Effects of scopolamine and D-cycloserine on non-spatial reference memory in rats. Behav Brain Res 129:211-216
11. Andreassen OA, Waage J, Finsen B, Jorgensen HA (2003) Memantine attenuates the increase in striatal preproenkephalin mRNA expression and development of haloperidol induced persistent oral dyskinesias in rats. Brain Res 994:188-192
12. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY (1997) Clozapine and haloperidol modulate NMDA- and non-NMDA receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226-234
13. Bacich DJ, Ramadan E, O'Keefe DS, Bukhari N, Wegorzewska I, Ojeifo O, Olszewski R, Wrenn CC, Bzdega T, Wroblewska B, Heston WD, Neale JH (2002) Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. J Neurochem 83:20-29
14. Bakshi VP, Tricklebank M, Neijt HC, Lehmann-Masten V, Geyer MA (1999) Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-aspartate receptor antagonists in rats. J Pharmacol Exp Ther 288:643-652
15. Balla A, Hashim A, Burch S, Javitt DC, Lajtha A, Sershen H (2001a) Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum. Neurochem Res 26:1001-1006
16. Balla A, Koneru R, Smiley J, Sershen H, Javitt DC (2001b) Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology 25:157-164
17. Balla A, Sershen H, Serra M, Koneru R, Javitt DC (2003) Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release. Neuropsychopharmacology 28:34-44
18. Ballard TM, Pauly-Evers M, Higgins GA, Ouagazzal AM, Mutel V, Borroni E, Kemp JA, Bluethmann H, Kew JNC (2002) Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci 22:6713-6723
19. Bardgett ME, Wrona CT, Newcomer JW, Csernansky JG (1993) Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur J Pharmacol 230:245-250
20. Barinka C, Sacha P, Sklenar J, Man P, Bezouska K, Slusher BS, Konvalinka J (2004) Identification of N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci 13:1627-1635
21. Beardsley PM, Ratti E, Balster RL, Willetts J, Trist D (2002) The selective glycine antagonist gavestinel lacks phencyclidine-like behavioural effects. Behav Pharmacol 13:583-592
22. 4 and metabotropic glutamate receptors in cerebral cortex and striaturn in rat brain. Neurochem Res 26:345-352
23. Berger UV, Luthi-Carter R, Passani LA, Elkabes S, Black I, Konradi C, Coyle JT (1999) Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. J Comp Neurol 415:52-64
24. Bergeron R, Coyle JT, Tsai G, Greene RW (2005) NAAG reduces NMDA receptor current in CAI hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology 30:7-16
25. Bezzi P, Volterra A (2001) A neuron-glia signalling network in the active brain. Curr Opin Neurobiol 11:387-394
26. Bezzi P, Gundersen V, Galbete JL, Seifert G, Steinhäusser C, Pilati E, Volterra A (2004) Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate. Nat Neurosci 7:613-620
27. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN (1999) Differing effects of NMDA receptor subtype selective antagonists on dyskinesia in levodopa treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 290:1034-1040
28. Bräuner-Osborne H, Egebjerg J, Nielsen E, Madsen U, Krogsgaard-Larsen P (2000) Ligands for glutamate receptors: design and therapeutic prospects. J Med Chem 43:2609-2645
29. Breese GR, Knapp DJ, Moy SS (2002) Integrative role for serotonergic and glutamatergic mechanisms in actions of NMDA antagonists: relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neurosci Biobehav Rev 26:441-455
30. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel position emission tomography method. Proc Natl Acad Sci U S A 94:2569-2574
31. 123I]CNS 1261 and SPET. Ann NY Acad Sci 1003:364-367
32. Brimecombe JC, Gallagher MJ, Lynch DR, Aizenman E (1998) An NR2B point mutation affecting haloperidol and CP101,606 sensitivity of single recombinant NMDA receptors. J Pharmacol Exp Ther 286:627-634
33. Burbaeva GS, Boksha IS, Turishcheva MS, Vorobyeva EA, Savushkina OK, Tereshkina EB (2003) Glutamine synthetase and glutamate dehydrogenase in the prefrontal cortex of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:675-680
34. Buonanno A, Fischbach GD (2001) Neuregulin and ErbB receptor signalling pathways in the nervous system. Curr Opin Neurobiol 11:287-296
35. Bzdega P, Crowe SL, Ramadan ER, Sciarretta KH, Olszewski RT, Ojeifo OA, Rafalski VA, Wroblewska B, Neale JH (2004) The cloning and characterization of a second brain enzyme with NAAG peptidase activity. J Neurochem 89:627-635
36. Campbell CM, Butelman ER, Woods JH (1999) Effects of (+)-HA-966, CGS-19755, phencyclidine, and dizocilpine on repeated acquisition of response chains in pigeons: systemic manipulation of central glycine sites. J Pharmacol Exp Ther 289:521-527
37. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237-260
38. Caudle RM, Dubner R (1998) Ifenprodil blocks the excitatory effects of the opioid peptide dynorphin 1-17 on NMDA receptor-mediated currents in the CA3 region of the guinea pig hippocampus. Neuropeptides 32:87-95
39. 2L receptors. J Neurosci 24:8214-8222
40. 2 receptor-deficient mice. J Neurophysiol 85:659-670
41. Chatterton JE, Awobuluyi M, Premkumar LS, Takahashi H, Talantova M, Shin Y, Cul J, Tu S, Sevarino KA, Nakanishi N, Tong G, Lipton SA, Zhang D (2002) Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature 413:793-798
42. 1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J Neurophysiol 87:2324-2336
43. Chen LW, Wei LC, Lang B, Ju G, Chan YS (2001) Differential expression of AMPA receptor subunits in dopamine neurons of the rat brain: a double immunocytochemical study. Neuroscience 106:149-160
44. Chen L, Muhlhauser M, Yang CR (2003) Glycine transporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 89:691-703
45. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Cohen D (2002) Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 99:13675-13680
46. Clinton SM, Meador-Woodruff JH (2004a) Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology 29:1353-1362
47. Clinton SM, Meador-Woodruff JH (2004b) Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophr Res 69:237-253
48. Clinton SM, Haroutunian V, Davis KL, Meador-Woodruff JH (2003) Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry 160:1100-1109
49. Collier DA (2003) The genetics of schizophrenia: glutamate not dopamine? Eur J Pharmacol 480:177-184
50. Cook SP, Galve-Roperh I, del Pozo AM, Rodriguez-Crespo I (2002) Direct calcium binding results in activation of brain serine racemase. J Biol Chem 277:27782-27792
51. Cordi A, Lacoste JM, Audinot V, Millan MJ (1999) Design, synthesis and structure-activity relationships of novel strychnine-insensitive glycine receptor ligands. Bioorg Med Chem Lett 9:1409-1414
52. Coyle JT (1997) The nagging question of the function of N-acetylaspartylglutamate. Neurobiol Dis 4:231-238
53. Coyle JT, Tsai G (2004) NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol 59:491-515
54. Crow TJ (2004) Cerebral asymmetry and the lateralization of language: core deficits in schizophrenia as pointers to the gene. Curr Opin Psychiatry 17:97-106
55. Cubelos B, Gonzalez-Gonzalez IM, Gimenez C, Zafra F (2005) Amino acid transporter SNATs localizes to glial cells in the rat brain. Glia 49:230-244
56. Cull-Candy S, Brickley S, Farrant M (2001) NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 11:327-335
57. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65:1-105
58. Danysz W, Parsons CG (1998) Glycine and NMDA receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50:597-664
59. Deitmer JW, Broer A, Broer S (2003) Glutamine efflux from astrocytes is mediated by multiple pathways. J Neurochem 87:127-135
60. De Lima AD, Opitz T, Voigt T (2004) Irreversible loss of subpopulation of cortical interneurons in the absence of a glutamatergic network. Eur J Neurosci 19:2931-2943
61. De Miranda J, Santoro A, Engelender S, Wolosker H (2000) Human serine racemase: molecular cloning, genomic organization and functional analysis. Gene 256:183-188
62. Depoortere R, Decobert M, Cudennec A, Claustre Y, Terranova J, Françon D, Alonso R, Simiand J, Perrault G, Griebel G, Soubrié P, Scatton B (2004) SSR504734, a selective and reversible inhibitor of the glycine transporter type 1 (GLYT1): III) effects in tests predictive of antipsychotic activity. Int J Neuropsychopharmacol 7:S433
63. De Souza IEJ, McBean GJ, Meredith GE (1999) Chronic haloperidol treatment impairs glutamate transport in the rat striatum. Eur J Pharmacol 382:139-142
64. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J (2001) A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol 24:43-49
65. Di Maria E, Gulli R, Begni S, De Luca A, Bignotti S, Pasini A, Bellone E, Pizzuti A, Dallapiccola B, Novelli G, Ajmar F, Gennarelli M, Mandich P (2004) Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: a case-control study. Am J Med Genet 128B:27-29
66. Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev 51:7-61
67. Do KQ, Trabesinger AH, Kirsten-Krüger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuénod M (2000) Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 12:3721-3728
68. Dolinska M, Zablocka B, Sonnewald U, Albrecht J (2004) Glutamine uptake and expression of mRNA's of glutamine transporting proteins in mouse cerebellar and cerebral cortical astrocytes and neurons. Neurochem Int 44:75-89
69. Dracheva S, Marras SA, Elhaken SL, Kramer FR, Davis KL, Haroutunian V (2001) N-Methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 158:1400-1410
70. D'Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH (2000) IV Glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry 47:450-462
71. Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP (2004a) Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res 71:239-248
72. Duncan GE, Moy SS, Perez A, Eddy DM, Zinzow WM, Lieberman JA, Snouwaert JN, Koller BH (2004b) Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res 153:507-519
73. Dyker AG, Edwards KR, Fayad PB, Hormes JT, Lees KR (1999) Safety and tolerability of aptiganel hydrochloride in patients with acute ischemic stroke. Stroke 30:2038-2042
74. Elkin A, Kalidindi S, McGuffin P (2004) Have schizophrenia genes been found? Curr Opin Psychiatry 17:107-113
75. Erhardt S, Engberg G (2002) Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand 175:45-53
76. Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G (2001) Kynurenic acid levels are elevated in cerebro spinal fluid of patients with schizophrenia. Neurosci Lett 313:96-98
77. Erhardt S, Schwieler L, Emanuelsson C, Geyer M (2004) Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry 56:255-260
78. Ermilov M, Kremer I, Blanaru M, Bloch B, Neeman G, Javitt D, Heresco-Levy U (2004) Glutamatergic neurotransmission-associated amino acids: plasma levels and relation to symptoms. Int J Psychopharmacol 7:S285
79. Evins AE, Amico E, Shih V, Goff DC (1997) Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm 104:761-766
80. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC (2000) Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 157:826-828
81. Evins AE, Amico E, Posever TA, Toker R, Goff DC (2002) D-Cyclo-serine added to risperidone in primary negative symptoms of schizophrenia. Schizophr Res 56:19-23
82. Farber NB (2003) The NMDA receptor hypofunction model of psychosis. Ann NY Acad Sci 1003:119-130
83. Faustman WO, Bardgett M, Faull KF, Pfefferbaum A, Csernansky JG (1999) Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. Biol Psychiatry 45:68-75
84. Feng B, Tse HW, Skifter DA, Morley R, Jane DE, Monaghan DT (2004) Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid. Br J Pharmacol 141: 508-516
85. Fitzgerald LW, Deutsch AY, Gassic G, Heinemann SE, Nestler EJ (1995) Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic. Drugs J Neurosci 95:2453-2461
86. Flores C, Coyle JT (2003) Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine. Neuropsychopharmacology 28:1227-1234
87. Fujita T, Kishida T, Wada M, Okada N, Yamamoto A, Leibach FH, Ganapathy V (2004) Functional characterization of brain peptide transporter in rat cortex: identification of high-affinity type H+/peptide transporter PEPT2. Brain Res 997:52-61
88. Fukumaki Y, Shibata H (2003) Glutamate receptor genes as candidates for schizophrenia susceptibility. Drug Dev Res 60:137-151
89. Gadea A, Lopez-Colomé AM (2001) Glial transporters for glutamate, glycine, and GABA III. Glycine transporters. J Neurosci Res 64:218-222
90. 4 receptor knockout mice. J Mol Neurosci 22:167-178
91. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA (2000) Ionotropic glutamate receptors and expression of NMDA receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 157:1141-1149
92. Garcia RA, Vasudevan K, Buonanno A (2000) The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at neuronal synapses. Proc Natl Acad Sci U S A 97:3596-3601
93. Garrido Sanabria ER, Wozniak KM, Slusher BS, Keller A (2004) GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. J Neurophysiol 91:182-193
94. Gemperle AY, Enz A, Pozza MF, Lüthi A, Olpe HR (2003) Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study. Neuroscience 117:681-695
95. Georges F, Aston-Jones G (2002) Activation of ventral tegmental area cells by the bed nucleus of the stria terminalis: a novel excitatory amino acid input to midbrain dopamine neurons. J Neurosci 22:5173-5187
96. Gerber DJ, Hall D, Miyakawa T, Demars S, Gogos JA, Karayiorgou M, Tonegawa S (2003) Evidence for association of schizophrenia with variation in the 8p21.3 gene PPP3CC encoding calcineurin gamma subunit. Proc Natl Acad Sci U S A 100:8993-8998
97. Gerlai R, Pisacane P, Erickson S (2000) Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioural tasks. Behav Brain Res 109:219-227
98. Geyer MA, Kreba-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117-154
99. Ghose S, Weickert CS, Colvin SM, Coyle JT, Herman MM, Hyde TM, Kleinman JE (2004) Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsychopharmacology 29:117-125
100. Gluck MR, Thomas RG, Haroutunian V (2002) Implications of altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry 159:1165-1173
101. Goebel DJ, Poosch MS (1999) NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1, NR2A, NR2B, NR2C, NR2D and NR3A. Brain Res Mol Brain Res 69:164-170
102. Goff DC, Tsai G, Monoach DS, Flood J, Darby DG, Coyle JT (1996) D-Cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153:1628-1630
103. Goff DC, Tsai G, Levitt J, Amico E, Monoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21-27
104. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, Johnson SA, Lynch G (2001) A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 21:484-487
105. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF (2002) Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 51:493-497
106. Golub MS, Germann SL, Lloyd KC (2004) Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse. Behav Brain Res 153:159-170
107. Gonzalez MI, Robinson MB (2004) Protein kinase C-dependent remodelling of glutamate transporter function. Mol Interv 4:48-58
108. Grimwood S, Slater P, Deakin JFW (1999) NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. NeuroReport 10:461-465
109. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW, Greene RW (1996) NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 16:2034-2043
110. Gundersen V, Talgoy Holten A, Strom-Mathisen J (2004) GABAergic synapses in hippocampus exocytose aspartate on to NMDA receptors: quantitative immunogold evidence for co-transmission. Mol Cell Neurosci 26:156-165
111. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA (2001) Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 98:4746-4751
112. 11C]L-703,717, a PET radioligand for the glycine-binding site of NMDA receptors. Synapse 50:130-136
113. Harrison PJ, Owen MJ (2003) Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361:417-419
114. Harrison PJ, Law AJ, Eastwood SL (2003) Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann NY Acad Sci 1003:94-101
115. Harsing LG, Gacsalyi I, Szabo G, Schmidt E, Sziray N, Sebban C, Tesolin-Decros B, Matyus P, Egyed A, Spedding M, Levay G (2003) The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem Behav 74:811-825
116. Hashimoto A, Chiba Y (2004) Effect of systemic administration of D-serine on the levels of D- and L-serine in several brain areas and periphery of rat. Eur J Pharmacol 495:153-158
117. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M (2003) Decreased serum levels of D-serine in patients with schizophrenia. Arch Gen Psychiatry 60:572-576
118. 1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry 9:299-307
119. 2 receptors and sigma receptors affect differently the NMDA-induced increase in intracellular calcium concentration: involvement of protein kinase. Synapse 31:20-28
120. Hedou G, Mansuy IM (2003) Inducible molecular switches for the study of long-term potentiation. Philos Trans R Soc Lond B Biol Sci 358:797-804
121. Heikkilä L, Rimon R, Terenius L (1990) Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients. Psychiatry Res 34:229-236
122. Helboe L, Egebjerg J, Moller M, Thomsen C (2003) Distribution and pharmacology of alanine-serine-cysteine transporter 1 (asc-1) in rodent brain. Eur J Neurosci 18:2227-2238
123. Heresco-Levy U (2000) NMDA receptor-based treatment approaches in schizophrenia: the first decade. Int J Neuropsychopharmacol 3:243-258
124. Heresco-Levy U (2003) Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1113-1123
125. Heresco-Levy U, Javitt DC (2004) Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 66:89-96
126. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Shimoni J (1998) Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 1:131-136
127. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29-36
128. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC (2002) Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 159:480-482
129. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC (2004) High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 55:165-171
130. Higgins GA, Ballard TM, Huwyler J, Kemp JA, Gill R (2003) Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition. Neuropharmacology 44:324-341
131. Hosak L, Libiger J (2002) Antiepileptic drugs in schizophrenia: a review. Eur Psychiatry 17:371-378
132. Humphries CR, Mortimer A, Hirsch SR (1996) NMDA receptor RNA correlation with antemortem cognitive impairment in schizophrenia. NeuroReport 7:2051-2055
133. Husi H, Ward MA, Choudhary IS, Blackstock WP, Grant SGN (2000) Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat Neurosci 3:661-669
134. 1 subunit isoforms in Alzheimer's disease. J Neurochem 89:240-247
135. Ibrahim HM, Hogg AJ, Healy DJ, Harountunian V, Davis KL, Meador-Woodruff JH (2000) Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 157:1811-1823
136. Ichinohe A, Kure S, Mikawa S, Ueki T, Kojima K, Fujiwara K, Linuma K (2004) Glycine cleavage system in neurogenic regions. Eur J Neurosci 19:2365-2370
137. Ilyin VI, Whittemore ER, Guastella J, Weber E, Woodward RM (1996) Subtype-selective inhibition of NMDA receptors by haloperidol. Mol Pharmacol 50:1541-1550
138. Ishimaru M, Kurumaji A, Toru M (1994) Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol Psychiatry 35:84-95
139. Itokawa MK, Yamada K, Yoshitsugu K (2003) A microsatellite repeat in the promoter of the NMDA receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. Pharmacogenetics 13:271-278
140. Iwamoto T, Yamada Y, Hori K, Watanabe Y, Sobue K, Inui M (2004) Differential modulation of NR1-NR2A and NR1-NR2B subtypes of NMDA receptor by PDZ domain-containing proteins. J Neurochem 89:100-108
141. Jackson ME, Homayoun H, Moghaddam B (2004) NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci U S A 101:8467-8472
142. Jang MK, Mierke DF, Russek SJ, Farb DH (2004) A steroid modulatory domain on NR2B controls NMDA receptor proton sensitivity. Proc Natl Acad Sci U S A 101:8198-8203
143. Jardemark KE, Ninan I, Liang X, Wang RY (2003) Protein kinase C is involved in clozapine's facilitation of NMDA- and electrically evoked responses in pyramidal cells of the medial prefrontal cortex. Neuroscience 118:501-512
144. Javitt DC (2002) Glycine modulators in schizophrenia. Curr Opin Investig Drugs 3:1067-1072
145. Javitt DC, Frusciante M (1997) Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse. Psychopharmacology 129:96-98
146. Javitt DC, Sershen H, Hashim A, Lajtha A (1997) Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 17:202-204
147. Javitt DC, Balla A, Sershen H, Lajtha A (1999) Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry 45:668-679
148. Javitt DC, Sershen H, Hashim A, Lajtha A (2000) Inhibition of striatal dopamine release by glycine and glycyldodecylamide. Brain Res Bull 52:213-216
149. Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, Lindenmayer JP, Suckow R, Zukin SR (2001) Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 4:385-391
150. Javitt DC, Balla A, Sershen H (2002) A novel alanine-insensitive D-serine transporter in rat brain synaptosomal membranes. Brain Res 941:146-149
151. Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H (2004a) Reversal of phencyclidine-induced dopaminergic dysregulation by NMDA receptor/glycine- site agonists. Neuropsychopharmacology 29:300-307
152. Javitt DC, Duncan L, Balla A, Sershen H (2004b) Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry, in press
153. Johannesen TS, Myhrer T (2002) Impaired visual memory in rats reared in isolation is reversed by D-cycloserine in the adult rat. Eur J Pharmacol 437:73-77
154. Jones R, Laake K, Oeksengaard AR (2004) D-Cycloserine for Alzheimer's disease (Cochrane review). In: The Cochrane Library, Issue 2. Wiley, Chichester, UK
155. Johnson SA, Luu NT, Herbst TA, Knapp R, Lutz D, Arai A, Rogergs GA, Lynch G (1999) Synergistic interactions between ampakines and antipsychotic drugs. J Pharmacol Exp Ther 289:392-397
156. Kadotani H, Hirano T, Masugi M, Nakamura K, Nakao K, Katsuki M, Nakanishi S (1996) Motor discoordination results from combined gene disruption of the NMDA receptor NR2A and NR2C subunits, but not from single disruption of the NR2A or NR2C subunit. J Neurosci 16:7859-7867
157. Kanamori K, Ross BD (2004) Quantitative demonstration of extracellular glutamine concentrations in rat brain, and its elevation in vivo by system A transporter inhibitor, alpha-(methylamino) isobutyrate. J Neurochem 90:203-210
158. Kane JM, Krystal J, Correll CU (2003) Treatment models and designs for intervention research during the psychotic prodrome. Schizophr Bull 29:747-756
159. 2 receptors - implications for models of schizophrenia. Mol Psychiatry 7:837-844
160. Kato K, Shishido T, Ono M, Shishido K, Kobayashi M, Niwa S (2001) Glycine reduces novelty- and methamphetamine-induced locomotor activity in neonatal ventral hippocampal damaged rats. Neuropsychopharmacolgy 24:330-332
161. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48:627-640
162. Kegeles LS, Martinez D, Kochan LD, Hwang DR, Huang Y, Mawlawi O, Suckow RF, Van Heertum DR, Laruelle M (2002) NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 43:19-29
163. Kinney GG, Sur C, Burno M, Mallorga PJ, Williams JB, Figueros DJ, Wittmann M, Lemaire W, Conn PJ (2003) The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4″-phenyl-phnoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci 23:7586-7591
164. Kloda A, Clements JD, Lewis RJ, Adams DJ (2004) Adenosine triphosphate acts as both a competitive antagonist and a positive allosteric modulator at recombinant NMDA receptors. Mol Pharmacol 65:1386-1396
165. Konradi C, Heckers S (2003) Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 97:153-179
166. Korostishevsky M, Kaganovich M, Cholostoy A, Ashkenazi M, Ratner Y, Dehary D, Bernstein J, Bening-Abu-Shach U, Ben-Asher E, Lancet D, Ritsner M, Navon R (2004) Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol Psychiatry 56:169-176
167. Kretschmer BD (1998) Ligands of the NMDA receptor-associated glycine recognition site and motor behavior. Amino Acids 14:227-234
168. Kretschmer BD, Koch M (1998) The ventral pallidum mediates disruption of prepulse inhibition of the acoustic startle response induced by dopamine agonists, but not by NMDA antagonists. Brain Res 798:204-210
169. Krupp JJ, Vissel B, Thomas CG, Heinemann SF, Westbrook GL (2002) Calcineurin acts via the C-terminus of NR2A to modulate desensitisation of NMDA receptors. Neuropharmacology 42:593-602
170. Kumashiro S, Hashimoto A, Nishikawa T (1995) Free D-serine in post-mortem brains and spinal cords of individuals with and without neuropsychiatric diseases. Brain Res 681:117-125
171. Lahti AC, Weiler MA, Michaelidis T, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455-467
172. Laruelle M, Kegeles LS, Abi-Dargham A (2003) Glutamate, dopamine, and schizophrenia from pathophysiology to treatment. Ann NY Acad Sci 1003:138-158
173. Law AJ, Deakin JFW (2001) Asymmetrical reduction of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. NeuroReport 12:2971-2974
174. Law AJ, Weickert S, Hyde TM, Kleinman JE, Harrison PJ (2004) Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. Neuroscience 127:125-136
175. Lee J, Rajakumar N (2003) Role of NR2B-containing NMDA receptors in haloperidol-induced c-FOS in striatum and nucleus accumbens. Neuroscience 122:739-745
176. Lees KR, Lavelle JF, Cunha L, Diener HC, Sanders EACM, Tack P, Wester P (2001) Glycine antagonist (GV150526) in acute stroke a multicentre, double-blind placebo-controlled phase II trial. Cerebrovasc Dis 11:20-29
177. Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC (1996) Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. Biol Psychiatry 39:213-215
178. Le Pen G, Kew J, Alberati D, Borroni E, Heitz MP, Moreau JL (2003) Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and glycine transporter inhibitor. Biol Psychiatry 54:1162-1170
179. Leveque JC, Macias W, Rajadhyaksha A, Carlson RR, Barczak A, Kang S, Li XM, Coyle JT, Huganir RL, Heckers S, Konradi C (2000) Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci 20:4011-4020
180. Levine JB, Martin G, Wilson A, Treistman SN (2003) Clozapine inhibits isolated NMDA receptors expressed in Xenopus oocytes in a subunit specific manner. Neurosci Lett 346:125-128
181. Lewis DA, Levitt P (2002) Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25:409-432
182. Lipska BK (2004) Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci 29:282
183. Lipsky RH, Goldman D (2003) Genomics and variation of ionotropic glutamate receptors. Ann NY Acad Sci 1003:22-35
184. Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, Auberson YP, Wang YT (2004) Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 304:1021-1024
185. Lowe DA, Emre M, Frey P, Kelly PH, Malanowski J, McAllister KH, Neijt HC, Rudeberg C, Urwyler S, White TG (1994) The pharmacology of SDZ EAA 494, a competitive NMDA antagonist. Neurochem Lett 25:583-600
186. Mackenzie S, Erickson JD (2004) Sodium-coupled neutral amino acid (system N/A) transporters of the SLC38 gene family. Pflugers Arch 447:784-795
187. Madden DR (2002) The structure and function of glutamate receptor ion channels. Nat Rev Neurosci 3:91-101
188. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A (1997) Clozapine blunts NMDA antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 42:664-668
189. Marcaggi P, Attwell D (2004) Role of glial amino acid transporters in synaptic transmission and brain energetics. Glia 47:217-225
190. Marenco S, Egan MF, Goldberg TE, Knable MB, McClure RK, Winterer G, Weinberger DR (2002) Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res 57:221-226
191. Marino MJ, Conn PJ (2002) Direct and indirect modulation of the NMDA receptor: potential for the development of novel antipsychotic therapies. Curr Drug Targets 1:1-16
192. Mathé JM, Nomikos GG, Schilström B, Svensson TH (1998) Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res 51:583-592
193. Matsuo H, Kanai Y, Tokunaga M, Nakata T, Chairoungdua A, Ihimine H, Tsukada S, Ooigawa H, Nawashiro H, Kobayashi Y, Fukuda J, Endou H (2004) High affinity D- and L-serine transporter Asc-1: cloning and dendritic localization in the rat cerebral and cerebellar cortices. Neurosci Lett 358:123-126
194. Matute C, Melone M, Vallejo-Illarramendi A, Conti F (2005) Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenia. Glia 49:451-455
195. Meador-Woodruff JH, Healy DJ (2000) Glutamate receptor expression in schizophrenia brain. Brain Res Interactive 31:288-294
196. Meador-Woodruff JH, Clinton SM, Beneyto M, McCullumsmith RE (2003) Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia. Ann NY Acad Sci 1003:75-93
197. Medoff DR, Holcomb HH, Lahti AC, Tamminga CA (2001) Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus 11:543-550
198. Melone M, Gragina L, Conti F (2003) Clozapine-induced reduction of glutamate transport in the frontal cortex is not mediated by GLAST and EAAC1. Mol Psychiatry 8:12-13
199. Meltzer LT, Christoffersen CL, Serpa KA (1997) Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci Biobehav Rev 21:511-518
200. Michel FJ, Trudeau LE (2000) Clozapine inhibits synaptic transmission at GABAergic synapses established ventral tegmental area neurones in culture. Neuropharmacology 39:1536-1543
201. B receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr Drug Targets 1:191-213
202. 2A site for PCP-induced locomotion in the rat. Eur J Neurosci 11:4419-4432
203. B receptors of potential utility for the treatment of psychotic disorders. Int J Psychopharmacol 3:S133
204. Miller RF (2004) D-Serine as a glial modulator of nerve cells. Glia 47:275-283
205. Miyakawa T, Leiter LM, Gerber DJ, Gainetdinov RR, Sotnikova TD, Zeng H, Caron MG, Tonegawa S (2003) Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A 100:8987-8992
206. 1 subunit. J Neurosci 21:750-757
207. Miyamoto S, Snouwaert JN, Koller BH, Moy SS, Lieberman JA, Duncan GE (2004) Amphetamine-induced fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunction. Neuropsychopharmacology:1-9
208. Miyatake R, Furukawa A, Suwaki H (2002) Identification of a novel variant of the human NR2B gene promoter regions and its possible association with schizophrenia. Mol Psychiatry 7:1101-1106
209. Moghaddam B (2002) Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry 51:775-787
210. Moghaddam B (2003) Bringing order to the glutamate chaos in schizophrenia. Neuron 40:881-884
211. Moghaddam B, Jackson ME (2003) Glutamatergic animal models of schizophrenia. Ann NY Acad Sci 1003:131-137
212. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98:427-436
213. Montana V, Ni Y, Sunjura V, Hua X, Parpura V (2004) Vesicular glutamate transporter-dependent glutamate release from astrocytes. J Neurosci 24:2633-2642
214. 1 explain the molecular recognition of agonist and antagonist ligands. J Struct Biol 145:205-215
215. Morgan CJA, Mofeez A, Brandner B, Bromley L, Curran HV (2004) Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29:208-218
216. Mothet JP, Parent AT, Wolosker H, Brady RO, Linden DJ, Ferris CD, Rogawski MA, Snyder SH (2000) D-Serine is an endogenous ligand for the glycine site of the NMDA receptor. Proc Natl Acad Sci U S A 97:4926-4931
217. Mueller HT, Haroutunian V, Davis KL, Meador-Woodruff JH (2004) Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Mol Brain Res 121:60-69
218. Muir KW, Lees KR (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke 26:503-513
219. +-independent transporter for small neutral amino acids that transports D-serine with high affinity. Neurosci Lett 287:231-235
220. 1 and NMDA-R1 receptors - a double immunofluorescence study. FENS FORUM, 414
221. Neale JH, Bzdega T, Wroblewska B (2000) N-Acetylaspartyl-glutamate: most abundant peptide neurotransmitter in mammalian central nervous system. J Neurochem 75:443-452
222. Nedergaard M, Takano T, Hansen AJ (2002) Beyond the role of glutamate as a neurotransmitter. Nat Rev Neurosci 3:748-755
223. Ninan I, Jardemark KE, Liang X, Wang RY (2003a) Calcium/ calmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells. Synapse 47:285-294
224. Ninan I, Jardemark KE, Wang RY (2003b) Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of NMDA receptors in pyramidal cells of the rat medial prefrontal cortex. Neuropharmacology 44:462-472
225. Nong YI, Huang YQ, Ju W, Kalia LV, Ahmadian G, Wang YT, Salter MW (2003) Glycine binding primes NMDA receptor internalisation. Nature 422:302-307
226. Ohnuma T, Tessler G, Arai H, Faull RL, McKenna PJ, Emson PC (2000) Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Res Mol Brain Res 85:24-31
227. Ohtsuki T, Sakurai K, Dou H, Toru M, Yamakawa-Kobayashi K, Arinami T (2001) Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia. Mol Psychiatry 6:211-216
228. Olszewski RT, Bukhari N, Zhou J, Kozikowski AP, Wroblewski JT, Shamimi-Noori S, Wroblewska B, Bzdega T, Vicini S, Barton FB, Neale JH (2004) NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem 89:876-885
229. Oranje B, Gispen-de Wied CC, Verbaten MN, Kahn RS (2002) Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol. Biol Psychiatry 52:557-895
230. Ossowska K, Pietraszek M, Wardas J, Nowak G, Wolfarth S (1999) Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn-Schmiedeberg's Arch Pharmacol 359:280-287
231. Parpura V, Scemes E, Spray DC (2004) Mechanisms of glutamate release from astrocytes: gap junction "hemichannels", purinergic receptors and exocytotic release. Neurochem Int 45:259-264
232. Paul IA, Skolnick P (2003) Glutamate and depression clinical and preclinical studies. Ann NY Acad Sci 1003:250-272
233. Perry W, Light GA, Davis H, Braff DL (2000) Schizophrenia patients demonstrate a dissociation on declarative and non-declarative memory tests. Schizophr Res 46:167-174
234. Popken GJ, Leggio MG (2002) Expression of mRNAs related to the GABAergic and glutamatergic neurotransmitter systems in the human thalamus: normal and schizophrenic. Thalamus Relat Syst 1:349-369
235. Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B (1999) Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 156:145-147
236. Pralong E, Magistretti P, Stoop R (2002) Cellular perspectives on the glutamate-monoamine interactions in limbic lobe structures and their relevance for some psychiatric disorders. Prog Neurobiol 67:173-202
237. B receptor partial agonist on amphetamine-induced sensitisation in mice. Pol J Pharmacol 51:385-390
238. Reisberg B, Doody R, Stöffler A (2003) Memantine in moderate to severe Alzheimer's disease. N Engl J Med 348:1333-1341
239. Ribeiro CS, Reis M, Panizzutti R, de Miranda J, Wolosker H (2002) Glial transport of the neuromodulator D-serine. Brain Res 929:202-209
240. 4 receptors are heterogeneously distributed in the striosomes/matrix compartment of the striatum. J Neurochem 80:219-229
241. Rodriguez JJ, Pickel VM (1999) Enhancement of NMDA immunoreactivity in residual dendritic spines in the caudate-putamen nucleus after chronic haloperidol administration. Synapse 33:289-303
242. Rosse RB, Theut SK, Banay-Schwartz M, Leighton M, Scarcella E, Cohen CG, Deutsch SI (1989) Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia an open-label, pilot study. Clin Neuropharmacol 12:416-424
243. Rouaud T, Billard JM (2003) D-Cycloserine facilitates synaptic plasticity but impairs glutamate neurotransmission in rat hippocampus slices. Br J Pharmacol 140:1051-1056
244. Rubin Y, La Placa MC, Smith DH, Thibault LE, Lenkinski RE (1995) The effect of N-acetylaspartate on the intracellular free calcium concentration in NTera2-neurons. Neurosci Lett 198:209-212
245. Sakata Y, Owada Y, Sato K, Kojima K, Hisanaga K, Shinka T, Suzuki Y, Aoki Y, Satoh J, Kondo H, Matsubara Y, Kure S (2001) Structure and expression of the glycine cleavage system in rat central nervous system. Mol Brain Res 94:119-130
246. Schell MJ, Molliver ME, Snyder SH (1995) D-Serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc Natl Acad Sci U S A 92:3948-3952
247. Schiffer HH (2002) Glutamate receptor genes. Mol Neurobiol 25:191-212
248. Schiffer WK, Logan J, Dewey SL (2003) Positron emission tomography studies of potential mechanisms underlying phencyclidine-induced alterations in striatal dopamine. Neuropsychopharmacology 28:2192-2198
249. Schmidt WJ, Kretschmer BD (1997) Behavioural pharmacology of glutamate receptors in the basal ganglia. Neurosci Biobehav Rev 21:381-392
250. Schmidt A, Zink M, Petroianu G, May B, Braus DF, Henn FA (2003) Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain. Neurosci Lett 347:81-84
251. Schneider J, Wade T, Lidsky T (1998) Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 Mma in the striatum. NeuroReport 9:133-136
252. Schoepp DD, Marek GJ (2002) Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr Drug Targets CNS Neurol Disord 1:215-225
253. Schroeder H, Greekseh G, Beeker A, Bogerts B, Hoellt V (1999) Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampus lesion. Psychopharmacology 145:61-66
254. Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M, Albus M, Lere B, Rietschel M, Trixler M, Maier W, Wildenauer DB (2003) Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 72:185-190
255. Schwarcz R, Pellicciari R (2002) Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303:1-10
256. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521-530
257. Schwieler L, Erhardt S (2003) Inhibitory action of clozapine on rat ventral tegmental area dopamine neurons following increased levels of endogenous kynurenic acid. Neuropsychopharmacology 28:1770-1777
258. Schwieler L, Engberg G, Erhardt S (2004) Clozapine modulates mid-brain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse 52:114-122
259. 5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci U S A 98:301-306
260. 2A-receptors. Br J Pharmacol 135:65-78
261. See RE, Lynch AM (1996) Duration-dependent increase in striatal glutamate following prolonged fluphenazine administration in rats. Eur J Pharmacol 302:279-282
262. Semple CAM, Devon RS, Le Hellard S, Porteous DJ (2001) Identification of genes from a schizophrenia-linked translocation breakpoint region. Genomics 73:123-126
263. Serretti A, De Ronchi D, Lorenzi C, Barardi D (2004) New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem 11:343-358
264. Sesack SR, Carr DB, Omelchenko N, Pinto A (2003) Anatomical substrates for glutamate-dopamine interactions. Ann NY Acad Sci 1003:36-52
265. Sheinin A, Shavit S, Benveniste M (2001) Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology 41:151-158
266. Sherman AD, Davidson AT, Baruah S, Hegwood TS, Waziri B (1991) Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett 121:77-80
267. Shi WX, Zhang XX (2003) Dendritic glutamate-induced bursting in the prefrontal cortex: further characterization and effects of phencyclidine. J Pharmacol Exp Ther 305:680-687
268. Shoham S, Mazeh H, Javitt DC, Heresco-Levy U (2004) Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia. Brain Res 1004:142-147
269. Smith RE, Haroutunian V (2001a) Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry 158:1393-1399
270. Smith RE, Haroutunian V (2001b) Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. NeuroReport 12:1-3
271. Speno HS, Luthi-Carter R, Macias WL, Valentine SL, Joshi ART, Coyle JT (1999) Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol Pharmacol 55:179-185
272. Spooren W, Mombereau C, Maco M, Gill R, Kemp JA, Ozmen L, Nakanishi S, Higgins GA (2004) Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition. Psychopharmacology 175:99-105
273. A) receptors. Neurochem Res 23:1283-1290
274. 1 and susceptibility to schizophrenia. Am J Hum Genet 71:877-892
275. 1 and schizophrenia. Ann Med 36:62-71
276. Stefensen SC, Svingos AL, Pickel VM, Henriksen SJ (1998) Electrophysiological characterization of GABAergic neurons in ventral tegmental area. J Neurosci 18:8003-8015
277. Steinpreis RE (1996) The behavioural and neurochemical effects of phencyclidine in humans and animals: some implications for modelling psychosis. Behav Brain Res 74:45-55
278. Stone TW, Darlington LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1:609-620
279. Stouffer EM, Petri HL, Devan BD (2004) Effect of D-serine on a delayed match-to-place task for the water maze. Behav Brain Res 152:447-452
280. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, Harris-Kerr C, Wormley B, Sadek H, Kadambi B, Cesare AJ, Gibberman A, Wang X, O'Neill FA, Walsh D, Kendler KS (2002) Genetic variation in 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 71:337-348
281. Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY (2004) Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropharmacol 7:1-8
282. 1 receptor potentiates NMDA receptor activity. Proc Natl Acad Sci U S A 100:13674-13679
283. Takahata R, Moghaddam B (2003) Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 28:1117-1124
284. Tamminga CA, Lahti AC, Mefoff DR, Gao XM, Holcomg HH (2003) Evaluating glutamatergic transmission in schizophrenia. Ann NY Acad Sci 1003:113-118
285. Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ (1999) Genetic enhancement of learning and memory in mice. Nature 401:63-69
286. Tanii Y, Nishikawa T, Hashimoto A, Takahashi K (1994) Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. J Pharmacol Exp Ther 269:1040-1048
287. Tarazi FI, Baldessarini RJ, Kula NS, Zhang H (2003) Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 306:1145-1151
288. Terada T, Inui K (2004) Peptide transporters: structure, function, regulation and application for drug delivery. Curr Drug Metab 5:85-94
289. Théberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, Neufeld RW, Rogers J, Pavlosky W, Schaefer B, Densmore M, Al-Semaan Y, Williamson PC (2002) Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 159:1944-1946
290. Théberge J, Al-Semann Y, Williamson PC, Menon RS, Neufeld RWJ, Rajakumar N, Schaefer B, Densmore M, Drost DJ (2003) Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 160:2231-2233
291. Tibbo P, Hanstock C, Valiakalayil A, Allen P (2004) 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 161:1116-1118
292. Tiihonen J, Hallikainen T, Ryynänen OP, Repo-Tiihonen E, Kotilainen I, Eronen M, Toivonen P, Wahlbeck K, Putkonen A (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 54:1241-1248
293. Toth E, Lajtha A (1986) Antagonism of phencyclidine induced hyperactivity by glycine in mice. Neurochem Res 11:393-400
294. Trudeau LE (2004) Glutamate co-transmission as an emerging concept in monoamine neuron function. Rev Psychiatr Neurosci 29:296-310
295. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brain. Arch Gen Psychiatry 52:829-836
296. Tsai G, Yang P, Chung LC, Lange N, Coyle JT (1998) D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081-1089
297. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT (1999) D-Serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 156:1822-1825
298. Tsai G, Lane HY, Yang P, Chong MY, Lang N (2004a) Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 55:452-456
299. Tsai G, Ralph-Williams RJ, Martina M, Bergeron R, Berger-Sweeney J, Dunham KS, Jiang Z, Caine SB, Coyle JT (2004b) Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc Natl Acad Sci U S A 101:8485-8490
300. Tseng KY, O'Donnell P (2004) Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signalling mechanisms. J Neurosci 24:5131-5139
301. Tuominen HJ, Tiihonen J, Wahlbeck K (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72:225-234
302. Turecek R, Vlcek K, Petrovic M, Horak M, Vlachova V, Vyklicky L (2004) Intracellular spermine decreases open probability of NMDA receptors. Neuroscience 125:879-887
303. Urai Y, Jinnouchi O, Kwak KT, Suzue A, Nagahiro S, Fukui K (2002) Gene expression of D-amino acid oxidase in cultured rat astrocytes regional and cell type specific expression. Neurosci Lett 324:101-104
304. Vaillend C, Ungerer A, Billard JM (1999) Facilitated NMDA receptor-mediated synaptic plasticity in the hippocampal CA1 area of dystrophin-deficient mice. Synapse 33:59-70
305. Van Berckel BNM (2003) Glutamate and schizophrenia. Curr Neuropharmacol 1:351-370
306. Van der Heijden FMMA, Tuinier S, Fekkes D, Sijben AES, Kahn RS, Verhoenven WMA (2004) Atypical antipsychotics and the relevance of glutamate and serotonin. Eur Neuropsychopharmacol 14:259-265
307. Ventriglia M, Bocchi Chiavetto L, Bonvicini C, Tura GB, Bignotti S, Racagni G, Gennarelli M (2002) Allelic variation in the human prodynorphin gene promoter and schizophrenia. Neuropsychobiology 46:17-21
308. Vicini S, Wang JF, Li JH, Zhu WJ, Wang YH, Luo JH, Wolfe BB, Grayson DR (1998) Functional and pharmacological differences between recombinant NMDA receptors. J Neurophysiol 79:555-566
309. Vieira AR, Devlin AM (2004) Glutamate carboxipeptidase II (GCPII) His475Tyr polymorphism and association studies. Am J Med Gen 130A:329-330
310. Weickert CS, Straub RE, McClintock BW, Matsumoto M, Hashimoto R, Hyde TM, Herman MM, Weinberger DR, Kleinman JE (2004) Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry 61:544-555
311. 1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177:207-216
312. Williams NM, Bowen T, Spurlock G, Norton N, Williams HJ, Hoogendoom B, Owen MJ, O'Donovan MC (2002) Determination of the genomic structure and mutation screening in schizophrenic individuals for five subunits of the NMDA glutamate receptor. Mol Psychiatry 7:508-514
313. 1 and susceptibility to schizophrenia. Mol Psychiatry 8:485-487
314. Williams JB, Mallorga PJ, Conn PJ, Pettibone DJ, Sur C (2004) Effects of typical and atypical antipsychotics on human glycine transporters. Schizophr Res 71:103-112
315. Winter JC, Eckler JR, Rabin RA (2003) Serotonergic/glutamatergic interactions: the effects of mGlu (2/3) receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology 172:233-240
316. Wollemann M, Benyhe S (2004) Non-opioid actions of opioid peptides. Life Sci 75:257-270
317. Wolosker H, Blackshaw S, Snyder SH (1999) Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci U S A 96:13409-13414
318. 2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 61:649-657
319. Xia M, Liu Y, Figueroa DJ, Chiu CS, Wei N, Lawlor AM, Lu P, Sur C, Koblan KS, Connolly TM (2004) Characterization and localization of a human serine racemase. Mol Brain Res 125:96-104
320. Yamakura T, Shimoh K (1999) Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol 59:279-298
321. Yamamoto BK, Pehek EA, Meltzer HY (1994) Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 55:8-14
322. Yan HD, Ishihara K, Serikawa T, Sasa M (2003) Activation by N-acetyl-L-aspartate of acutely dissociated hippocampal neurons in rats via metabotropic glutamate receptors. Epilepsia 44:1153-1159
323. Yanahashi S, Hashimoto K, Hattori K, Yuasa S, Iyo M (2004) Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol. Brain Res 1011:84-93
324. 1 gene with schizophrenia. Mol Psychiatry 8:706-709
325. Ye ZC, Wyeth MS, Baltan-Tekkok S, Ransom BR (2003) Functional hemichannels in astrocytes: a novel mechanism of glutamate release. J Neurosci 23:3588-3596
326. A synaptic receptors. Neuroscience 113:1-10
327. Zavitsanou K, Ward PB, Huang XF (2002) Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology 27:826-833